StimLabs, LLC. Announces Growing Portfolio with New Product: Enverse™

04 July 2022 | Monday | News


StimLabs, LLC ("StimLabs"), a leader in regenerative technologies and products that are revolutionizing patient care through innovation and personalized solutions, today announced the launch of a new placental membrane-based product, Enverse

StimLabs is expanding their product portfolio to address the widening range of needs in healthcare facilities. The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems in which they practice. Both physician owned and hospital owned facilities now have StimLabs' solutions at their disposal.

Enverse is a translucent dehydrated complete human placental membrane (dCHPM) allograft designed for use as a wound covering over acute and chronic wounds. The dCHPM allograft is processed to retain the intermediate layer using the patented Clearify™ method. This allograft is stabilized using a patented oven-dehydration process, resulting in a compact, translucent format.  Enverse allows for increased application site visibility while maintaining excellent handling characteristics.1

StimLabs' differentiated placental membrane-based product portfolio remains of the highest quality with each product processed using StimLabs' patented Clearify process. StimLabs takes a scientific approach to process development, encompassing the identification, optimization, and retention of native structures and structural components found in birth tissue. With the ultimate goal of preserving all the potential that birth tissue offers, StimLabs continues to innovate the tissue space and deliver market-leading products.

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close